$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

$vrdn Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000159075022000004 Filed on March 11, 2022

Income Statement

Concept	2021 Q4	2021 Q1	2021
Revenue	$214.0K	$1.451M	$2.963M
YoY Change	328.0%	75.24%	182.19%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.901M	$6.160M	$25.81M
YoY Change	24.57%	126.47%	94.46%
% of Gross Profit
Research & Development	$22.38M	$13.81M	$56.89M
YoY Change	46.96%	126.22%	100.98%
% of Gross Profit
Depreciation & Amortization	$32.00K	$33.00K	$100.0K
YoY Change	-36.0%	-51.47%	-50.0%
% of Gross Profit
Operating Expenses	$29.30M	$19.97M	$82.69M
YoY Change	41.11%	126.22%	-25.79%
Operating Profit		-$18.52M	-$79.73M
YoY Change		131.5%	-27.77%
Interest Expense	$135.0K	$60.00K	$315.0K
YoY Change	-196.43%	-220.0%	-192.65%
% of Operating Profit
Other Income/Expense, Net		$55.00K	$318.0K
YoY Change		-42.11%	83.82%
Pretax Income	-$28.95M	-$18.46M	-$79.41M
YoY Change	-68.1%	129.6%	-28.28%
Income Tax
% Of Pretax Income
Net Earnings	-$28.95M	-$18.46M	-$79.41M
YoY Change	-68.1%	129.49%	-28.27%
Net Earnings / Revenue	-13526.17%	-1272.23%	-2680.16%
Basic Earnings Per Share		-$2.91	-$6.66
Diluted Earnings Per Share	-$1.303M	-$2.91	-$6.66
COMMON SHARES
Basic Shares Outstanding	21.72M shares	6.336M shares	11.92M shares
Diluted Shares Outstanding		6.336M shares	11.92M shares

Balance Sheet

Concept	2021 Q4	2021 Q1	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$197.0M	$117.1M	$197.0M
YoY Change	54.36%	224.38%	54.36%
Cash & Equivalents	$42.30M	$46.49M	$42.30M
Short-Term Investments	$154.7M	$70.60M	$154.7M
Other Short-Term Assets	$2.747M	$3.100M	$2.747M
YoY Change	37.35%	40.91%	37.35%
Inventory
Prepaid Expenses
Receivables	$451.0K	$1.400M	$451.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$200.2M	$121.5M	$200.2M
YoY Change	54.43%	216.98%	54.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$375.0K	$148.0K	$2.055M
YoY Change	21.36%	-66.59%	156.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.491M	$1.000K	$1.491M
YoY Change	149000.0%		65.67%
Total Long-Term Assets	$3.546M	$1.298M	$3.546M
YoY Change	115.69%	83.07%	108.59%
TOTAL ASSETS
Total Short-Term Assets	$200.2M	$121.5M	$200.2M
Total Long-Term Assets	$3.546M	$1.298M	$3.546M
Total Assets	$203.7M	$122.8M	$203.7M
YoY Change	55.2%	214.55%	55.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.329M	$3.384M	$2.329M
YoY Change	247.61%	107.73%	232.71%
Accrued Expenses	$11.02M	$12.76M	$11.02M
YoY Change	13.55%	317.81%	13.59%
Deferred Revenue	$289.0K	$288.0K
YoY Change	-3.99%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.64M	$16.44M	$13.64M
YoY Change	27.75%	89.77%	27.44%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$1.208M	$33.00K	$2.357M
YoY Change	2709.3%		371.4%
Total Long-Term Liabilities	$1.208M	$33.00K	$2.357M
YoY Change	2709.3%	-99.03%	371.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.64M	$16.44M	$13.64M
Total Long-Term Liabilities	$1.208M	$33.00K	$2.357M
Total Liabilities	$15.99M	$16.83M	$15.99M
YoY Change	42.57%	39.7%	42.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$358.3M	-$297.3M
YoY Change	28.47%	68.73%
Common Stock	$239.0K	$72.00K
YoY Change	469.05%	-86.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$187.7M	$106.0M	$187.7M
YoY Change
Total Liabilities & Shareholders Equity	$203.7M	$122.8M	$203.7M
YoY Change	55.2%	214.55%	55.15%

Cashflow Statement

Concept	2021 Q4	2021 Q1	2021
OPERATING ACTIVITIES
Net Income	-$28.95M	-$18.46M	-$79.41M
YoY Change	-68.1%	129.49%	-28.27%
Depreciation, Depletion And Amortization	$32.00K	$33.00K	$100.0K
YoY Change	-36.0%	-51.47%	-50.0%
Cash From Operating Activities	-$16.54M	-$11.54M	-$54.58M
YoY Change	75.17%	36.41%	83.29%
INVESTING ACTIVITIES
Capital Expenditures	-$84.00K	$15.00K	$338.0K
YoY Change	-940.0%		704.76%
Acquisitions
YoY Change
Other Investing Activities	-$80.13M	$10.89M	$0.00
YoY Change	52.8%	444.5%	-100.0%
Cash From Investing Activities	-$80.21M	$10.87M	-$74.29M
YoY Change	52.98%	443.33%	47.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$114.2M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	170.0K	$1.259M	$125.3M
YoY Change	-99.78%	-92.89%	23.65%
NET CHANGE
Cash From Operating Activities	-16.54M	-$11.54M	-$54.58M
Cash From Investing Activities	-80.21M	$10.87M	-$74.29M
Cash From Financing Activities	170.0K	$1.259M	$125.3M
Net Change In Cash	-96.58M	$592.0K	-$3.598M
YoY Change	-710.85%	-94.74%	-117.09%
FREE CASH FLOW
Cash From Operating Activities	-$16.54M	-$11.54M	-$54.58M
Capital Expenditures	-$84.00K	$15.00K	$338.0K
Free Cash Flow	-$16.45M	-$11.55M	-$54.92M
YoY Change	74.1%	36.59%	84.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001590750
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Registrant Name EntityRegistrantName	Viridian Therapeutics, Inc./DE
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-36483
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1187261
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	221 Crescent Street, Suite 401
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Waltham
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02453
CY2021	dei	City Area Code CityAreaCode	(617)
CY2021	dei	Local Phone Number LocalPhoneNumber	272-4600
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2021	dei	Trading Symbol TradingSymbol	VRDN
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	157400000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25913229	shares
CY2021	dei	Auditor Firm AuditorFirmId	185
CY2021	dei	Auditor Name AuditorName	KPMG LLP
CY2021	dei	Auditor Location AuditorLocation	Boulder, Colorado
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42299000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45897000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	154666000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	81742000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2747000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1972000	USD
CY2021Q4	vrdn	Unbilled Receivables Related Party Current UnbilledReceivablesRelatedPartyCurrent	451000	USD
CY2020Q4	vrdn	Unbilled Receivables Related Party Current UnbilledReceivablesRelatedPartyCurrent	0	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	200163000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	129611000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	375000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	309000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1680000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	478000	USD
CY2021Q4	vrdn	Other Assets Related Party Noncurrent OtherAssetsRelatedPartyNoncurrent	0	USD
CY2020Q4	vrdn	Other Assets Related Party Noncurrent OtherAssetsRelatedPartyNoncurrent	856000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1491000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1000	USD
CY2021Q4	us-gaap	Assets Assets	203709000	USD
CY2020Q4	us-gaap	Assets Assets	131255000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2329000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	670000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11018000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9703000	USD
CY2021Q4	vrdn	Contract With Customer Liability Related Party Current ContractWithCustomerLiabilityRelatedPartyCurrent	289000	USD
CY2020Q4	vrdn	Contract With Customer Liability Related Party Current ContractWithCustomerLiabilityRelatedPartyCurrent	301000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13636000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10674000	USD
CY2021Q4	vrdn	Other Liabilities Related Party Noncurrent OtherLiabilitiesRelatedPartyNoncurrent	1149000	USD
CY2020Q4	vrdn	Other Liabilities Related Party Noncurrent OtherLiabilitiesRelatedPartyNoncurrent	501000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1208000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	43000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	15993000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	11218000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23924004	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23924004	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4231135	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4231135	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	239000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	42000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	412101000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	218089000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-157000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-358300000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-278887000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	187716000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	120037000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	203709000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	131255000	USD
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2963000	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1050000	USD
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	56886000	USD
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	28304000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25805000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13265000	USD
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	69861000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	82691000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	111430000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-79728000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-110380000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	318000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	173000	USD
CY2021	us-gaap	Interest And Debt Expense InterestAndDebtExpense	3000	USD
CY2020	us-gaap	Interest And Debt Expense InterestAndDebtExpense	508000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-79413000	USD
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3557065	shares
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-110715000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-149000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-8000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-79562000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-110723000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-79413000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-79413000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-110715000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-110715000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.66
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.66
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-31.13
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-31.13
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11918712	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11918712	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3557065	shares
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	39000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	15754000	USD
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	95361000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit	47000	USD
CY2020	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	6000000	USD
CY2020	vrdn	Stock Issued During Period Value Warrants Exercised Value StockIssuedDuringPeriodValueWarrantsExercisedValue	550000	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	29000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	26000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3629000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	16000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-8000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-110715000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	120037000	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2021	vrdn	Stock Issued During Period Value Warrants Exercised Value StockIssuedDuringPeriodValueWarrantsExercisedValue	1285000	USD
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1027000	USD
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	7500000	USD
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	7500000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14442000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	23000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-149000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-79413000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	187716000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-79413000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-110715000	USD
CY2021	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	USD
CY2020	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	65990000	USD
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	6000000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	14465000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	3645000	USD
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	87000	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	281000	USD
CY2021	us-gaap	Accretion Expense AccretionExpense	0	USD
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-77000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	159000	USD
CY2020	us-gaap	Accretion Expense AccretionExpense	263000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	120000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	239000	USD
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-965000	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-56000	USD
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	4000	USD
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-35000	USD
CY2021	vrdn	Non Cash Lease Expense NonCashLeaseExpense	-102000	USD
CY2020	vrdn	Non Cash Lease Expense NonCashLeaseExpense	0	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1496000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1655000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-426000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1380000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5012000	USD
CY2021	vrdn	Increase Decrease In Unbilled Revenue IncreaseDecreaseInUnbilledRevenue	451000	USD
CY2020	vrdn	Increase Decrease In Unbilled Revenue IncreaseDecreaseInUnbilledRevenue	0	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	636000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-54581000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29779000	USD
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	188431000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	81807000	USD
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	67538000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2021	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2020	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	29371000	USD
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	46860000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	2000000	USD
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	10293000	USD
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	79000	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	338000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	42000	USD
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	3000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-74292000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-50481000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	114242000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1285000	USD
CY2020	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1027000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	39000	USD
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1726000	USD
CY2021	vrdn	Payment For Fractional Share Payment Reverse Stock Split PaymentForFractionalSharePaymentReverseStockSplit	0	USD
CY2020	vrdn	Payment For Fractional Share Payment Reverse Stock Split PaymentForFractionalSharePaymentReverseStockSplit	44000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	125275000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	101311000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3598000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	21051000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45897000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24846000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42299000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45897000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	267000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2021	vrdn	Amortization Of Stock Issuance Costs AmortizationOfStockIssuanceCosts	87000	USD
CY2020	vrdn	Amortization Of Stock Issuance Costs AmortizationOfStockIssuanceCosts	32000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-358300000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	197000000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for clinical trial costs and other outsourced research and development expenses, and the valuation of share-based awards. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</span></div>
CY2019	vrdn	Restructuring And Related Cost Number Of Plan Phases RestructuringAndRelatedCostNumberOfPlanPhases	2	plan_phase
CY2020	vrdn	Restructuring And Related Cost Number Of Plan Phases RestructuringAndRelatedCostNumberOfPlanPhases	2	plan_phase
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-8000	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.</span></div>
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-100000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	USD
CY2020	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	127710000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	197022000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	163000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	196865000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	127702000	USD
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	4000	USD
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2151000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3752000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1776000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3443000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	375000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	309000	USD
CY2021Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	100000	USD
CY2021	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	100000	USD
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-100000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	USD
CY2021Q4	vrdn	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	6316000	USD
CY2020Q4	vrdn	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	5400000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3652000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	796000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1963000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	520000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	455000	USD
CY2021Q4	vrdn	Accrued Legal Fees Current AccruedLegalFeesCurrent	80000	USD
CY2020Q4	vrdn	Accrued Legal Fees Current AccruedLegalFeesCurrent	380000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	140000	USD
CY2021Q4	vrdn	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	100000	USD
CY2020Q4	vrdn	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	100000	USD
CY2021Q4	vrdn	Accrued License Agreement Liability Current AccruedLicenseAgreementLiabilityCurrent	0	USD
CY2020Q4	vrdn	Accrued License Agreement Liability Current AccruedLicenseAgreementLiabilityCurrent	86000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	210000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	523000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11018000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9703000	USD
CY2021	vrdn	Lessee Operating Lease Number Of Renewal Terms LesseeOperatingLeaseNumberOfRenewalTerms	3	renewal_term
CY2021Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1600000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1600000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.06
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12M
CY2021Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	200000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	100000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	100000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.06
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1900000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	500000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1200000	USD
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	500000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	300000	USD
CY2021Q1	vrdn	Capital Stock Shares Authorized CapitalStockSharesAuthorized	205000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	300000	USD
CY2021	vrdn	Operating Leases Operating Expense OperatingLeasesOperatingExpense	300000	USD
CY2020	vrdn	Operating Leases Operating Expense OperatingLeasesOperatingExpense	300000	USD
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q1	vrdn	Common Stock Voteper Share CommonStockVoteperShare	1	vote
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	vrdn	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Net ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet	420629	shares
CY2020Q4	vrdn	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Net ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet	498500	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	15.91
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	498500	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	16.00
CY2021	vrdn	Class Of Warrant Or Right Exercised In Period ClassOfWarrantOrRightExercisedInPeriod	77871	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	420629	shares
CY2021	vrdn	Class Of Warrant Or Right Exercised In Period Weighted Average Grant Date Fair Value ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue	16.50
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3683839	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2155945	shares
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14465000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3645000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	45100000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y2M1D
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23010000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28099000	shares
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.083
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.015
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.004
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.013
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.285
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.158
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.129
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.009
CY2021	vrdn	Effective Income Tax Rate Reconciliation Section382 Limit Percent EffectiveIncomeTaxRateReconciliationSection382LimitPercent	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	vrdn	Effective Income Tax Rate Reconciliation Section382 Limit Percent EffectiveIncomeTaxRateReconciliationSection382LimitPercent	-0.249
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.023
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.002
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	40992000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22622000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1686000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	494000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3055000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2037000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3123000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1571000	USD
CY2021Q4	vrdn	Deferred Tax Assets Tax Deferred Expense Startup Costs DeferredTaxAssetsTaxDeferredExpenseStartupCosts	5013000	USD
CY2020Q4	vrdn	Deferred Tax Assets Tax Deferred Expense Startup Costs DeferredTaxAssetsTaxDeferredExpenseStartupCosts	2467000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	53869000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	29191000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	53430000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29073000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	439000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	118000	USD
CY2021Q4	vrdn	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	439000	USD
CY2020Q4	vrdn	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	118000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	439000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	118000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020	vrdn	Tax Credit Carryforward Limitations On Use Amount TaxCreditCarryforwardLimitationsOnUseAmount	59000000	USD
CY2020	vrdn	Tax Credit Carryforward Limitations On Use Amount TaxCreditCarryforwardLimitationsOnUseAmount	59000000	USD
CY2020	vrdn	Tax Credit Carryforward Write Off TaxCreditCarryforwardWriteOff	15300000	USD
CY2021Q4	vrdn	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	53400000	USD
CY2020Q4	vrdn	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	29100000	USD
CY2020	vrdn	Deferred Tax Asset Valuation Allowance Percent DeferredTaxAssetValuationAllowancePercent	1
CY2021	vrdn	Deferred Tax Asset Valuation Allowance Percent DeferredTaxAssetValuationAllowancePercent	1
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	24400000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	17200000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0	USD

Files In Submission

Name	View Source	Status
0001590750-22-000004-index-headers.html	Edgar Link	pending
0001590750-22-000004-index.html	Edgar Link	pending
0001590750-22-000004.txt	Edgar Link	pending
0001590750-22-000004-xbrl.zip	Edgar Link	pending
ex104subscriptionagreement.htm	Edgar Link	pending
ex23_1xfinalconsentx2021.htm	Edgar Link	pending
ex31_vrdnxsecondrestatedce.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
fy202110kex211.htm	Edgar Link	pending
fy202110kex311.htm	Edgar Link	pending
fy202110kex312.htm	Edgar Link	pending
fy202110kex321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vrdn-20211231.htm	Edgar Link	pending
vrdn-20211231.xsd	Edgar Link	pending
vrdn-20211231_cal.xml	Edgar Link	unprocessable
vrdn-20211231_def.xml	Edgar Link	unprocessable
vrdn-20211231_g1.jpg	Edgar Link	pending
vrdn-20211231_g2.jpg	Edgar Link	pending
vrdn-20211231_g3.jpg	Edgar Link	pending
vrdn-20211231_g4.jpg	Edgar Link	pending
vrdn-20211231_htm.xml	Edgar Link	completed
vrdn-20211231_lab.xml	Edgar Link	unprocessable
vrdn-20211231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

2021 Q4 Form 10-K Financial Statement

#000159075022000004 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN Viridian Therapeutics, Inc.\DE Stock $vrdn

2021 Q4 Form 10-K Financial Statement

#000159075022000004 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn